Premium
Effect of soy protein isolate on glycemic control in adults with type 2 diabetes
Author(s) -
Gobert Colleen P,
Phillips Elizabeth A,
Capes Sarah E,
Darlington Gerarda A,
Lampe Johanna W,
Duncan Alison M
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a369-c
Subject(s) - postprandial , glycemic , medicine , type 2 diabetes , glycated hemoglobin , crossover study , soy protein , diabetes mellitus , endocrinology , insulin , placebo , alternative medicine , pathology
Evidence from observational, animal and cell culture studies support a role for soy protein and its isoflavones in the improvement of glycemic control in type 2 diabetes. The objective of this study was to determine the effect of isoflavone‐rich soy protein on markers of glycemic control in adults with type 2 diabetes. Using a double‐blind, randomized, crossover, placebo‐controlled intervention study design, adults with diet‐controlled type 2 diabetes (n=29) consumed SPI or milk protein isolate (MPI) for 57 days each separated by a 4‐week washout period. Fasting blood samples were collected on days 1 and 57 of each treatment period for analysis of fasting plasma glucose and glycated hemoglobin (HbA1C). An oral glucose tolerance test was also performed on days 1 and 57 of each treatment period for analysis of postprandial plasma glucose. Results showed no significant differences between treatments for fasting HbA1C, fasting plasma glucose or postprandial plasma glucose response, as summarized by area under the curve. These data do not support a role for soy protein in the improvement of glycemic control in adults with type 2 diabetes and contribute to a limited literature on the effects of soy protein on the management of type 2 diabetes. Supported by the Heart and Stroke Foundation of Ontario and the Solae Company.